股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 創美藥業股份有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02289 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 108,000,000 | RMB | | 1 RMB | | 108,000,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 108,000,000 | RMB | | 1 RMB | | 108,000,000 | 本月底法定/註冊股本總額： RMB 108,000,000 備註： 因本 ...

主要由于(1)宏观经济增速放缓，上下游行业景气度承压，且2024年第一季度基数较高，2025年第一季 度同比下降20.52%，营业收入阶段性下滑。面对市场挑战，公司迅速调整经营策略，主营业务收入自 第二季度实现恢复性增长，2025年第二季度同比增长6.48%；及(2)药品集采政策深化导致部分药品终端 价格下降，部分药品业务量有所收缩。 格隆汇8月29日丨创美药业(02289.HK)公告，截至2025年6月30日止6个月中期业绩，集团的营业收入同 比减少8.18%至人民币21.55亿元；归属于母公司股东的净利润2173.9万元，同比减少18.72%；基本及稀 释每股收益0.2013。 ...

智通财经APP讯，创美药业(02289)发布截至2025年6月30日止六个月中期业绩，营业总收入21.55亿元 (人民币，下同)，同比减少8.18%;归母净利润2173.9万元，同比减少18.72%;基本每股收益0.2013元。 ...

创美药业(02289)发布截至2025年6月30日止六个月中期业绩，营业总收入21.55亿元(人民币，下同)，同 比减少8.18%;归母净利润2173.9万元，同比减少18.72%;基本每股收益0.2013元。 ...

[Interim Results Announcement](index=1&type=section&id=Interim%20Results%20Announcement) This announcement presents the unaudited consolidated interim results of Chuangmei Pharmaceutical Co., Ltd. for the six months ended June 30, 2025, providing an overview of the Group's key financial performance during this reporting period [Performance Summary](index=1&type=section&id=Performance%20Summary) For the six months ended June 30, 2025, the Group's operating revenue, total profit, net profit attributable to parent company shareholders, and earnings per share all decreased year-on-year, reflecting macroeconomic pressures and market policy adjustments Key Financial Indicators for the Six Months Ended June 30 | Indicator | 2025 (RMB thousand) | 2024 (RMB thousand) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 2,155,071 | 2,347,185 | -8.18% | | Total Profit | 32,629 | 38,928 | -16.18% | | Net Profit Attributable to Parent Company Shareholders | 21,739 | 26,747 | -18.72% | | Basic and Diluted Earnings Per Share (RMB) | 0.2013 | 0.2477 | -18.73% | [Consolidated Financial Statements](index=2&type=section&id=Consolidated%20Financial%20Statements) This section presents the unaudited consolidated income statement and balance sheet of Chuangmei Pharmaceutical Co., Ltd. and its subsidiaries for the six months ended June 30, 2025, detailing the Group's operating results and financial position [Consolidated Income Statement](index=2&type=section&id=Consolidated%20Income%20Statement) For the six months ended June 30, 2025, the Group's total operating revenue was RMB 2,155.07 million, and net profit was RMB 21.74 million, with all profitability indicators showing a downward trend compared to the same period in 2024 Consolidated Income Statement Key Data (For the Six Months Ended June 30) | Item | 2025 (RMB) | 2024 (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 2,155,071,479.51 | 2,347,184,933.33 | | Total Operating Costs | 2,115,726,066.82 | 2,303,414,061.34 | | Operating Profit | 33,032,573.22 | 39,341,323.61 | | Total Profit | 32,628,791.19 | 38,927,943.68 | | Net Profit | 21,739,023.67 | 26,747,235.53 | | Net Profit Attributable to Parent Company Shareholders | 21,739,023.67 | 26,747,235.53 | | Basic and Diluted Earnings Per Share (RMB/share) | 0.2013 | 0.2477 | [Consolidated Balance Sheet](index=4&type=section&id=Consolidated%20Balance%20Sheet) As of June 30, 2025, the Group's total assets were RMB 3,492.25 million, a slight increase from year-end 2024, while total current liabilities were RMB 2,826.38 million and total shareholders' equity was RMB 591.83 million, both decreasing from year-end 2024 Consolidated Balance Sheet Key Data (As of June 30) | Item | June 30, 2025 (RMB) | December 31, 2024 (RMB) | | :--- | :--- | :--- | | Total Current Assets | 3,079,169,763.07 | 3,029,992,834.71 | | Total Non-current Assets | 413,081,710.51 | 426,650,847.62 | | Total Assets | 3,492,251,473.58 | 3,456,643,682.33 | | Total Current Liabilities | 2,826,380,478.56 | 2,788,603,021.09 | | Total Non-current Liabilities | 74,041,023.36 | 49,349,713.25 | | Total Liabilities | 2,900,421,501.92 | 2,837,952,734.34 | | Total Equity Attributable to Parent Company Shareholders | 591,829,971.66 | 618,690,947.99 | | Total Shareholders' Equity | 591,829,971.66 | 618,690,947.99 | | Total Liabilities and Shareholders' Equity | 3,492,251,473.58 | 3,456,643,682.33 | [Notes to the Condensed Consolidated Interim Financial Statements](index=6&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Interim%20Financial%20Statements) This section provides detailed notes to the unaudited condensed consolidated interim financial statements, covering company information, basis of preparation, significant accounting policies, and specific data explanations, to enhance understanding of the financial statements [General Information](index=6&type=section&id=General%20Information) Chuangmei Pharmaceutical Co., Ltd. was incorporated in China in 1984 and listed on the HKEX in 2015, primarily engaged in pharmaceutical trade and related services, with financial statements presented in RMB - The company was incorporated in China in 1984 and listed on the Main Board of the Hong Kong Stock Exchange on **December 14, 2015**[9](index=9&type=chunk) - The Group's principal business is pharmaceutical trade and related services[10](index=10&type=chunk) - The condensed consolidated interim financial statements are presented in **RMB**, which is the functional currency of the Company[11](index=11&type=chunk) [Basis of Preparation of Financial Statements](index=6&type=section&id=Basis%20of%20Preparation%20of%20Financial%20Statements) The Group's financial statements are prepared in accordance with Chinese accounting standards, CSRC, and HKEX listing rules, based on a going concern principle, with no significant doubts about its ability to continue as a going concern - The financial statements are prepared in accordance with the **Accounting Standards for Business Enterprises** issued by the Ministry of Finance of China, **Information Disclosure and Compilation Rules for Companies Issuing Securities to the Public No. 15** issued by the China Securities Regulatory Commission, and the **Hong Kong Companies Ordinance** and **Listing Rules**[12](index=12&type=chunk) - The Group has assessed its ability to continue as a going concern for the **12 months** from June 30, 2025, and found no significant doubts, thus the financial statements are presented on a going concern basis[13](index=13&type=chunk) [Significant Accounting Policies and Accounting Estimates](index=6&type=section&id=Significant%20Accounting%20Policies%20and%20Accounting%20Estimates) The Group's financial statements comply with accounting standards, accurately reflecting financial position, operating results, and cash flows, with no changes in significant accounting policies or estimates during the reporting period - These financial statements comply with the requirements of the Accounting Standards for Business Enterprises, truly, accurately, and completely reflecting the financial position of the Company and the Group as of **June 30, 2025**, and the operating results and cash flows for the six months ended **June 30, 2025**[14](index=14&type=chunk) - The Group's accounting period is from **January 1 to December 31** of the Gregorian calendar, with an operating cycle of **12 months**, and the bookkeeping base currency is **RMB**[15](index=15&type=chunk)[16](index=16&type=chunk)[17](index=17&type=chunk) - There were no changes in the Group's significant accounting policies and major accounting estimates during the reporting period[19](index=19&type=chunk) [Operating Revenue and Operating Costs](index=7&type=section&id=Operating%20Revenue%20and%20Operating%20Costs) For the six months ended June 30, 2025, the Group's total operating revenue was RMB 2,155.07 million, primarily from main business, with total operating costs of RMB 1,994.33 million, both decreasing from 2024 Operating Revenue and Operating Costs Details (For the Six Months Ended June 30) | Item | 2025 Revenue (RMB) | 2025 Costs (RMB) | 2024 Revenue (RMB) | 2024 Costs (RMB) | | :--- | :--- | :--- | :--- | :--- | | Main Business | 2,128,769,934.11 | 1,992,617,151.90 | 2,325,459,578.61 | 2,177,837,790.01 | | Other Businesses | 26,301,545.40 | 1,708,944.88 | 21,725,354.72 | 162,213.00 | | Total | 2,155,071,479.51 | 1,994,326,096.78 | 2,347,184,933.33 | 2,178,000,003.01 | [Segment Information](index=7&type=section&id=Segment%20Information) The Group's business is considered a single operating and reporting segment: pharmaceutical distribution and related services, with all operating revenue and non-current assets generated within China - The Group has only one operating and reporting segment: **pharmaceutical distribution and related services**[21](index=21&type=chunk) - All of the Group's operations are located in China, and all operating revenue and non-current assets are generated in China[22](index=22&type=chunk) [Finance Costs](index=8&type=section&id=Finance%20Costs) For the six months ended June 30, 2025, the Group's finance costs were RMB 33.69 million, a 1.21% decrease year-on-year, primarily due to reduced interest expenses Finance Costs Details (For the Six Months Ended June 30) | Item | 2025 (RMB) | 2024 (RMB) | | :--- | :--- | :--- | | Interest Expense | 31,055,269.10 | 33,101,117.52 | | Of which: Bank borrowings and others | 29,621,637.63 | 32,244,615.80 | | Interest expense on lease liabilities | 885,458.13 | 856,501.72 | | Less: Interest income | 1,147,053.30 | 2,882,746.74 | | Add: Exchange gains/(losses) | 6,223.70 | -2,856.37 | | Add: Others | 3,775,286.67 | 3,887,182.98 | | Total | 33,689,726.17 | 34,102,697.39 | [Income Tax Expense](index=8&type=section&id=Income%20Tax%20Expense) For the six months ended June 30, 2025, the Group's income tax expense was RMB 10.89 million, a 10.60% decrease year-on-year, mainly comprising PRC corporate income tax and deferred tax, with no taxable income in Hong Kong Income Tax Expense Details (For the Six Months Ended June 30) | Item | 2025 (RMB) | 2024 (RMB) | | :--- | :--- | :--- | | Current income tax calculated according to tax laws and regulations | 11,519,164.74 | 12,309,195.72 | | —PRC corporate income tax | 11,519,164.74 | 12,309,195.72 | | —Hong Kong profits tax | | | | Deferred income tax expense | -629,397.22 | -128,487.57 | | Total | 10,889,767.52 | 12,180,708.15 | - The Group had no taxable income in Hong Kong, thus no Hong Kong income tax[24](index=24&type=chunk) [Return on Net Assets and Earnings Per Share](index=9&type=section&id=Return%20on%20Net%20Assets%20and%20Earnings%20Per%20Share) For the six months ended June 30, 2025, the weighted average return on net assets attributable to parent company shareholders was 3.79%, with basic and diluted earnings per share both at RMB 0.2013 Return on Net Assets and Earnings Per Share (For the Six Months Ended June 30) | Profit for the Reporting Period | Weighted Average Return on Net Assets (%) | Basic Earnings Per Share (RMB/share) | Diluted Earnings Per Share (RMB/share) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | 3.79 | 0.2013 | 0.2013 | | Net Profit Attributable to Parent Company Shareholders (Excluding Non-recurring Gains and Losses) | 3.84 | 0.2036 | 0.2036 | [Dividends](index=9&type=section&id=Dividends) The Board does not recommend an interim dividend for the six months ended June 30, 2025, consistent with the same period in 2024 - The Board does not recommend the payment of an interim dividend for the six months ended **June 30, 2025** (2024 interim dividend: nil)[27](index=27&type=chunk) [Bills Receivable](index=10&type=section&id=Bills%20Receivable) As of June 30, 2025, total bills receivable were RMB 35.97 million, a significant increase from year-end 2024, primarily commercial acceptance bills, with a corresponding increase in bad debt provision and RMB 3.60 million pledged Bills Receivable Classified (As of June 30) | Item | Balance as of June 30, 2025 (RMB) | Balance as of December 31, 2024 (RMB) | | :--- | :--- | :--- | | Commercial Acceptance Bills | 36,100,000.00 | 5,590,000.00 | | Less: Provision for Bad Debts | 126,350.00 | 19,565.00 | | Total | 35,973,650.00 | 5,570,435.00 | - As of **June 30, 2025**, the amount of pledged bills receivable was **RMB 3.60 million**, all of which were commercial acceptance bills[34](index=34&type=chunk) [Accounts Receivable](index=12&type=section&id=Accounts%20Receivable) As of June 30, 2025, net accounts receivable were RMB 1,183.82 million, a slight increase from year-end 2024, with the largest portion being within one year aging and total bad debt provision of RMB 21.52 million Net Accounts Receivable (As of June 30) | Item | Balance as of June 30, 2025 (RMB) | Balance as of December 31, 2024 (RMB) | | :--- | :--- | :--- | | Accounts Receivable | 1,205,335,300.45 | 1,184,455,239.82 | | Less: Provision for Bad Debts | 21,518,255.45 | 21,217,687.43 | | Net Amount | 1,183,817,045.00 | 1,163,237,552.39 | Accounts Receivable by Aging (As of June 30) | Aging | Balance as of June 30, 2025 (RMB) | Balance as of December 31, 2024 (RMB) | | :--- | :--- | :--- | | Within 1 Year | 1,166,135,680.72 | 1,156,354,646.21 | | 1-2 Years | 24,808,526.12 | 13,018,971.27 | | 2-3 Years | 221,671.72 | 629,729.86 | | Over 3 Years | 14,169,421.89 | 14,451,892.48 | | Total | 1,205,335,300.45 | 1,184,455,239.82 | [Receivables Financing](index=14&type=section&id=Receivables%20Financing) As of June 30, 2025, receivables financing primarily consisted of bank acceptance bills totaling RMB 23.57 million, a significant decrease from RMB 57.62 million at year-end 2024 Receivables Financing (As of June 30) | Item | Balance as of June 30, 2025 (RMB) | Balance as of December 31, 2024 (RMB) | | :--- | :--- | :--- | | Bank Acceptance Bills | 23,573,149.39 | 57,615,292.39 | | Total | 23,573,149.39 | 57,615,292.39 | [Bills Payable](index=14&type=section&id=Bills%20Payable) As of June 30, 2025, bills payable primarily consisted of bank acceptance bills totaling RMB 709.19 million, a decrease from RMB 826.51 million at year-end 2024, with all bills payable due within one year Bills Payable (As of June 30) | Type of Bill | Balance as of June 30, 2025 (RMB) | Balance as of December 31, 2024 (RMB) | | :--- | :--- | :--- | | Bank Acceptance Bills | 709,194,022.88 | 826,507,576.48 | | Total | 709,194,022.88 | 826,507,576.48 | - All of the Group's bills payable at the end of the period have an aging of within **1 year**[45](index=45&type=chunk) [Accounts Payable](index=14&type=section&id=Accounts%20Payable) As of June 30, 2025, total accounts payable were RMB 364.79 million, a decrease from RMB 387.83 million at year-end 2024, mainly comprising goods and equipment payments, with the largest portion due within one year Accounts Payable Details (As of June 30) | Item | Balance as of June 30, 2025 (RMB) | Balance as of December 31, 2024 (RMB) | | :--- | :--- | :--- | | Goods Payments | 363,780,496.38 | 386,978,214.29 | | Equipment Payments | 1,006,410.04 | 847,499.25 | | Total | 364,786,906.42 | 387,825,713.54 | Accounts Payable by Aging (As of June 30) | Aging | Balance as of June 30, 2025 (RMB) | Balance as of December 31, 2024 (RMB) | | :--- | :--- | :--- | | Within 1 Year | 340,650,702.60 | 374,742,200.33 | | 1-2 Years | 22,025,835.02 | 11,505,873.92 | | 2-3 Years | 557,882.63 | 727,758.26 | | Over 3 Years | 1,552,486.17 | 849,881.03 | | Total | 364,786,906.42 | 387,825,713.54 | [Management Discussion and Analysis](index=15&type=section&id=Management%20Discussion%20and%20Analysis) This section details the macro environment, market trends, policy impacts, and the Group's business performance and future development strategies in China's pharmaceutical distribution industry, highlighting structural transformation and the importance of digitalization and intelligence [Industry Overview](index=15&type=section&id=Industry%20Overview) China's pharmaceutical distribution industry is undergoing profound changes driven by an aging population, deepening healthcare reforms, the "dual circulation" strategy, and digital innovation, leading to increased market concentration and a shift towards intelligent and diversified platforms [Market Trends and Policy Impact](index=15&type=section&id=Market%20Trends%20and%20Policy%20Impact) China's pharmaceutical distribution market is influenced by an aging society, healthcare reform policies like "volume-based procurement" and "tiered diagnosis," and the "dual circulation" strategy, leading to sustained growth in the retail market, especially online pharmacies and instant retail, and increased market concentration - China has officially entered a "moderately aging" society, with rising public health awareness driving a steady increase in demand for pharmaceutical and health services[48](index=48&type=chunk) - In 2024, the market share of China's retail pharmacies (including online pharmacies) continued to grow by **1.5 percentage points**; online pharmacy drug sales increased by **14.4% year-on-year**, and instant retail sales in pharmacies reached **RMB 48.7 billion**, a **31.3% year-on-year increase**[49](index=49&type=chunk) - Healthcare reform policies are accelerating the restructuring of the pharmaceutical market, with the out-of-hospital market rapidly benefiting from prescription outflow, projected to reach **RMB 1.6 trillion** by 2029[51](index=51&type=chunk)[52](index=52&type=chunk) - The National Healthcare Security Administration mandates that from **January 1, 2025**, "dual-channel" managed drugs must have prescriptions circulated through the national unified medical insurance electronic prescription center, completely replacing paper prescriptions[52](index=52&type=chunk) [Digital and Intelligent Transformation](index=17&type=section&id=Digital%20and%20Intelligent%20Transformation) The pharmaceutical industry is accelerating digital and intelligent transformation with the full implementation of drug traceability codes and comprehensive medical insurance QR code settlements, leveraging AI and big data to enhance supply chain efficiency and refined service capabilities - In **March 2025**, four departments including the National Healthcare Security Administration required active promotion of drug traceability codes for full-process, full-volume collection and full-scenario application in medical security and work-related injury insurance fields[55](index=55&type=chunk) - From **July 1, 2025**, designated medical institutions must scan codes at the point of sale to settle medical insurance funds; by **January 1, 2026**, all medical institutions must achieve full collection and upload of drug traceability codes[55](index=55&type=chunk) - The Implementation Plan for Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030) supports the application of digital intelligence technology to achieve full-process product traceability, ensuring product quality and safety[56](index=56&type=chunk) - Advanced technologies such as AI, big data, and cloud computing are deeply applied, leading the pharmaceutical distribution industry towards **digital intelligence, diversification, and platformization**[57](index=57&type=chunk) [Business Review](index=18&type=section&id=Business%20Review) The Group's core business is pharmaceutical distribution in China, focusing on Guangdong and surrounding markets, expanding its retail network. Despite a slight reduction in customer and product numbers, it enhances competitiveness through product optimization, brand collaboration, silver economy opportunities, AI empowerment, and logistics advantages [Core Business and Distribution Network](index=18&type=section&id=Core%20Business%20and%20Distribution%20Network) The Group primarily distributes pharmaceuticals in China, sourcing from manufacturers and suppliers to serve distributors, retail pharmacies, and private hospitals. As of June 30, 2025, its network covered 12,170 customers and 11,164 product types, a decrease from the previous year - The Group's principal business is pharmaceutical distribution in China, with the vast majority of operating revenue derived from pharmaceutical distribution[58](index=58&type=chunk) - As of **June 30, 2025**, the distribution network covered **12,170 customers**, including **575 distributors**, **7,965 retail pharmacies**, and **3,630 private hospitals, clinics, health stations, and others**, representing a decrease of **624 customers** compared to the same period last year[58](index=58&type=chunk) Product Quantity (For the Six Months Ended June 30) | Product Category | 2025 | 2024 | | :--- | :--- | :--- | | Proprietary Chinese Medicines | 4,067 | 4,445 | | Western Medicines | 4,184 | 4,316 | | Others | 2,913 | 2,835 | | Total | 11,164 | 11,596 | [Marketing Ecosystem and Product Portfolio](index=18&type=section&id=Marketing%20Ecosystem%20and%20Product%20Portfolio) The Group collaborates closely with brand pharmaceutical companies and downstream customers through a multi-dimensional marketing network, integrating resources, optimizing channels, and providing digital logistics to build a complete industry chain and business ecosystem, actively promoting "ten-million-level" brand client policies - The Group leverages its multi-dimensional marketing network advantages to collaborate closely with brand pharmaceutical companies and downstream customers, jointly building a complete industrial chain and business ecosystem[60](index=60&type=chunk) - It continues to deepen its product portfolio, actively promoting the **"ten-million-level" brand client policy**, and has successfully created multiple strategically cooperative brands with sales exceeding **RMB 10 million**[61](index=61&type=chunk) - The Group has innovatively built a multi-dimensional marketing system, establishing an efficient production-sales matching platform through brand co-marketing, event-driven marketing, and differentiated promotional strategies[61](index=61&type=chunk) - Focusing on the **silver economy**, the Group identifies and cultivates potential products that meet the health needs of the elderly population, working with quality partners to improve the silver health industry ecosystem[62](index=62&type=chunk) [AI Empowerment and Digital Transformation](index=19&type=section&id=AI%20Empowerment%20and%20Digital%20Transformation) The Group has successfully applied AI tools to key business areas like financial management, intelligent process optimization, and drug traceability, significantly improving operational efficiency and compliance, and has initiated AI pilot applications in critical logistics segments - The Group has successfully achieved automation in key business areas such as financial management, intelligent process engine optimization, efficient pharmaceutical data governance, intelligent commodity monitoring, and intelligent verification and compliance management of drug traceability codes[63](index=63&type=chunk) - AI tools have been piloted in critical logistics segments (e.g., intelligent warehouse management, delivery route optimization) to optimize resource allocation and decision-making efficiency[63](index=63&type=chunk) - Subsequently, the Group will gradually advance full-process digital integration to achieve an end-to-end intelligent business closed loop, and continuously iterate adaptive AI models to expand AI applications in new scenarios such as intelligent customer service and precise outreach[63](index=63&type=chunk) [Core Logistics Advantages and Third-Party Logistics](index=19&type=section&id=Core%20Logistics%20Advantages%20and%20Third-Party%20Logistics) As a leading modern pharmaceutical supply chain service provider in South China, the Group operates distribution centers in Guangzhou, Shantou, Shenzhen, and Zhuhai, equipped with cold chain and smart warehousing, efficiently meeting its own distribution needs and expanding third-party logistics services, with significant growth in related clients and revenue - The Group has established medium-to-large modern pharmaceutical distribution centers in Guangzhou, Shantou, Shenzhen, and Zhuhai, building a comprehensive logistics network and information system, strictly adhering to GSP management standards[64](index=64&type=chunk) - The distribution centers are equipped with advanced cold chain and refrigerated transport vehicles and intelligent warehousing equipment, capable of meeting differentiated pharmaceutical distribution needs[64](index=64&type=chunk) - During the reporting period, the number of clients for third-party pharmaceutical logistics entrusted services and other value-added services such as warehousing or transportation, in cooperation with manufacturers, commercial distributors, and chain pharmacies, increased by **15.23% year-on-year**, with corresponding revenue increasing by **21.52% year-on-year**[65](index=65&type=chunk) - The Group has consistently received multiple industry honors for many years, including "Best Pharmaceutical Cold Chain Logistics Center," "Recommended Pharmaceutical Cold Chain Logistics Service Enterprise," and "Excellent Pharmaceutical Logistics and Distribution Enterprise"[66](index=66&type=chunk) [Future Outlook](index=21&type=section&id=Future%20Outlook) The Group will adhere to its "deep cultivation in Guangdong, radiating to surrounding areas" strategy, fully advance AI-powered digital transformation, deepen strategic cooperation with brand manufacturers, strengthen core pharmaceutical logistics capabilities, expand third-party logistics, and explore new domestic and international industrial collaborations for high-quality development [Market Strategy](index=21&type=section&id=Market%20Strategy) The Group will maintain its "deep cultivation in Guangdong, radiating to surrounding areas" market strategy, building a comprehensive pharmaceutical retail network across Guangdong and neighboring regions, expanding and refining its distribution network to achieve dense coverage for sales, services, and logistics - The Group will continue to implement the **"deep cultivation in Guangdong, radiating to surrounding areas"** market strategy, building a comprehensive pharmaceutical retail network covering Guangdong Province and surrounding areas[69](index=69&type=chunk) - It will strengthen risk management, improve operational quality, seize opportunities from the expansion of the grassroots medical market, optimize network layout, and expand drug delivery coverage[69](index=69&type=chunk) [AI-Powered Digital Transformation](index=22&type=section&id=AI-Powered%20Digital%20Transformation) The Group will continue to deepen its "Smart Internet + Pharma" strategy, fully integrating digitalization and AI to build an intelligent supply chain ecosystem, deploying large-scale pre-trained models and AI agents to optimize processes, enhance organizational efficiency, and leverage data assets for AI-driven deep data analysis and precise decision-making - It will continue to deepen the **"Smart Internet + Pharma" strategy**, comprehensively promoting the deep integration of digitalization and AI technology, focusing on building a new intelligent supply chain ecosystem[70](index=70&type=chunk) - By systematically deploying large-scale pre-trained models and AI agents, it will optimize business processes, shift high-frequency repetitive tasks to automated intelligent processing, and enhance organizational efficiency[70](index=70&type=chunk) - Relying on its vast data assets in the pharmaceutical distribution sector, it will build an **AI-driven deep data analysis platform** to support scientific and forward-looking decision-making[70](index=70&type=chunk) [Deepening Strategic Cooperation with Brand Manufacturers](index=22&type=section&id=Deepening%20Strategic%20Cooperation%20with%20Brand%20Manufacturers) The Group will further deepen cooperation with brand manufacturers to secure more growth opportunities in non-tender markets, enrich its product portfolio, and expand into high-growth potential markets, leveraging its retail network to provide comprehensive brand promotion and product implementation support for suppliers - It will further deepen cooperation with various brand manufacturers to secure more growth opportunities for products shifting to non-tender markets and enrich its product portfolio[72](index=72&type=chunk) - Fully utilizing the Group's resources and advantages in the pharmaceutical retail network, it will build a vibrant innovative marketing ecosystem, providing upstream suppliers with comprehensive brand promotion and product implementation solutions and support services[72](index=72&type=chunk) [Strengthening Core Pharmaceutical Logistics Capabilities](index=23&type=section&id=Strengthening%20Core%20Pharmaceutical%20Logistics%20Capabilities) The Group will comprehensively integrate transport resources, advance smart logistics capabilities, enhance delivery services, and strengthen regional integrated logistics synergy, optimizing efficiency and cost control through multi-warehouse collaboration and intelligent scheduling, while actively expanding third-party pharmaceutical logistics services - It will comprehensively integrate existing transportation resources, promote the construction of smart logistics capabilities, further enhance delivery service capabilities, and strengthen the synergistic effect of regional integrated logistics[73](index=73&type=chunk) - Relying on a collaborative operating model of multi-warehouse linkage and intelligent scheduling, it aims to achieve optimal efficiency and cost control from source to terminal delivery[73](index=73&type=chunk) - It will actively expand third-party pharmaceutical logistics services, providing upstream suppliers and downstream customers with professional and convenient warehousing, logistics, and freight transportation, as well as more value-added services[73](index=73&type=chunk) [Pioneering New Domestic and International Industrial Cooperation](index=23&type=section&id=Pioneering%20New%20Domestic%20and%20International%20Industrial%20Cooperation) Leveraging state-owned shareholder resources, the Group will actively seek high-quality domestic and international products and strategic collaborations to build a more complete product supply chain, expand profitable new businesses, and optimize its business structure and profit model, consolidating its leading position in South China's non-tender pharmaceutical market - It will leverage the rich resources and advantages of its state-owned shareholders to actively seek high-quality domestic and international products and strategic collaborations, building a more complete product supply chain[74](index=74&type=chunk) - It will expand into more profitable new businesses, continuously optimizing its business structure and profit model, and promoting the deep integration of emerging technologies with core competitiveness[74](index=74&type=chunk) - It will consolidate its leading position in the non-tender pharmaceutical market in South China and continue to increase investment in digitalization and business innovation[74](index=74&type=chunk) [Financial Review](index=24&type=section&id=Financial%20Review) This section provides a detailed review of the Group's financial performance for the six months ended June 30, 2025, including changes in operating revenue, costs, gross profit, expenses, and net profit, along with an analysis of liquidity, asset-liability structure, and related risks [Operating Revenue](index=24&type=section&id=Operating%20Revenue) For the six months ended June 30, 2025, the Group's operating revenue was RMB 2,155.07 million, a year-on-year decrease of 8.18%, primarily due to slowing macroeconomic growth, a high base in Q1 2024, and declining drug prices from centralized procurement policies Operating Revenue by Business Type (For the Six Months Ended June 30) | Item | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Main Business | 2,128,770 | 2,325,460 | | Other Businesses | 26,302 | 21,725 | | Operating Revenue | 2,155,071 | 2,347,185 | Main Business Revenue by Customer Type (For the Six Months Ended June 30) | Customer Type | 2025 (RMB thousand) | 2024 (RMB thousand) | | :--- | :--- | :--- | | Distributors | 1,030,348 | 1,093,126 | | Retail Pharmacies | 1,040,097 | 1,151,208 | | Private Hospitals, Clinics, Health Stations, and Others | 58,325 | 81,126 | | Main Business Revenue | 2,128,770 | 2,325,460 | - Operating revenue decreased by **8.18% year-on-year**, primarily due to slowing macroeconomic growth, a high base in the first quarter of 2024 leading to a **20.52% year-on-year decrease** in the first quarter of 2025, and the deepening of drug centralized procurement policies resulting in lower terminal prices for some drugs[79](index=79&type=chunk) - Main business revenue achieved restorative growth in the second quarter, with a **6.48% year-on-year increase** in the second quarter of 2025[79](index=79&type=chunk) [Operating Costs, Gross Profit, and Gross Margin](index=24&type=section&id=Operating%20Costs%2C%20Gross%20Profit%2C%20and%20Gross%20Margin) For the six months ended June 30, 2025, operating costs decreased by 8.43% to RMB 1,994.33 million, slightly more than the revenue decline. Gross profit decreased by 4.99% to RMB 160.75 million, but gross margin increased by 0.25 percentage points to 7.46%, driven by lower procurement costs, product structure optimization, and growth in third-party logistics - Operating costs decreased by **8.43% year-on-year** to **RMB 1,994.33 million**, a decrease slightly higher than that of operating revenue[80](index=80&type=chunk) - Gross profit decreased by **4.99% year-on-year** to **RMB 160.75 million**[80](index=80&type=chunk) - Gross margin increased by **0.25 percentage points** from **7.21%** in the same period of 2024 to **7.46%** in the same period of 2025[80](index=80&type=chunk) - The improvement in gross margin was primarily due to leveraging channel advantages to reduce procurement costs, continuous adjustment of product structure to introduce high-margin products, and a **21.52% year-on-year increase** in third-party logistics business revenue[80](index=80&type=chunk)[81](index=81&type=chunk) [Selling Expenses](index=25&type=section&id=Selling%20Expenses) For the six months ended June 30, 2025, selling expenses decreased by 3.87% to RMB 60.44 million, primarily due to the company's efficient allocation of marketing resources and reduction of inefficient marketing channels - Selling expenses decreased by **3.87% year-on-year** to **RMB 60.44 million**[82](index=82&type=chunk) - This was mainly due to the Company's efficient allocation of marketing resources and the reduction of inefficient marketing channels[82](index=82&type=chunk) [Administrative Expenses](index=25&type=section&id=Administrative%20Expenses) For the six months ended June 30, 2025, administrative expenses decreased by 3.68% to RMB 22.47 million, mainly due to cost reduction and efficiency gains from digital office implementation, leading to reduced office, travel, and staff costs - Administrative expenses decreased by **3.68% year-on-year** to **RMB 22.47 million**[83](index=83&type=chunk) - This was mainly due to the implementation of digital office, resulting in a year-on-year decrease of **RMB 0.51 million** in office and travel expenses, and a year-on-year decrease of **RMB 0.46 million** in staff remuneration[83](index=83&type=chunk) [Finance Costs](index=25&type=section&id=Finance%20Costs) For the six months ended June 30, 2025, finance costs decreased by 1.21% to RMB 33.69 million, primarily due to a RMB 2.05 million reduction in interest expenses from lower borrowing rates - Finance costs decreased by **1.21% year-on-year** to **RMB 33.69 million**[84](index=84&type=chunk) - This was mainly due to a decrease in borrowing interest rates, leading to a year-on-year reduction of **RMB 2.05 million** in interest expenses[84](index=84&type=chunk) [Income Tax Expense](index=25&type=section&id=Income%20Tax%20Expense) For the six months ended June 30, 2025, income tax expense decreased by 10.60% to RMB 10.89 million, recognized in accordance with accounting standards for current income tax and adjustments to deferred tax assets and liabilities - Income tax expense decreased by **10.60% year-on-year** to **RMB 10.89 million**[85](index=85&type=chunk) - This was recognized in accordance with accounting standards for current income tax expense and adjustments to deferred tax assets and deferred tax liabilities[85](index=85&type=chunk) [Net Profit](index=25&type=section&id=Net%20Profit) For the six months ended June 30, 2025, net profit decreased by 18.72% to RMB 21.74 million, primarily due to slowing macroeconomic growth, high base effect leading to revenue decline, rigid cost structure, and a significant increase in credit impairment losses - Net profit decreased by **18.72% year-on-year** to **RMB 21.74 million**[86](index=86&type=chunk) - This was primarily due to slowing macroeconomic growth and a high base effect leading to a phased decline in operating revenue, coupled with a rigid cost structure, where expense optimization measures did not fully offset the pressure from narrowing gross profit[86](index=86&type=chunk) - Credit impairment losses significantly increased compared to the same period last year, negatively impacting net profit[86](index=86&type=chunk) [Liquidity and Financial Resources](index=25&type=section&id=Liquidity%20and%20Financial%20Resources) As of June 30, 2025, the Group held RMB 212.24 million in cash and bank balances, with net current assets of RMB 252.79 million and a current ratio of 1.09, largely consistent with year-end 2024, and total bank borrowings of RMB 1,010.88 million at fixed interest rates - As of **June 30, 2025**, the Group held cash and bank balances of **RMB 212.24 million**, an increase from **RMB 171.79 million** at December 31, 2024[87](index=87&type=chunk) - Net current assets were **RMB 252.79 million**, and the current ratio was **1.09**, largely consistent with December 31, 2024[87](index=87&type=chunk) - Total bank borrowings amounted to **RMB 1,010.88 million** (short-term borrowings of **RMB 967.68 million** and long-term borrowings of **RMB 43.20 million**), with all bank borrowings bearing fixed interest rates[88](index=88&type=chunk) [Bills Receivable, Accounts Receivable, and Receivables Financing](index=26&type=section&id=Bills%20Receivable%2C%20Accounts%20Receivable%2C%20and%20Receivables%20Financing) As of June 30, 2025, the combined total of bills receivable, accounts receivable, and receivables financing was RMB 1,243.36 million, a 1.38% increase from year-end 2024, remaining largely stable - As of **June 30, 2025**, the total amount of bills receivable, accounts receivable, and receivables financing was **RMB 1,243.36 million**, an increase of **1.38%** compared to December 31, 2024, remaining largely stable[89](index=89&type=chunk) [Bills Payable and Accounts Payable](index=26&type=section&id=Bills%20Payable%20and%20Accounts%20Payable) As of June 30, 2025, the combined total of bills payable and accounts payable was RMB 1,073.98 million, a 11.56% decrease from year-end 2024, primarily due to the Group's strategic procurement arrangements and effective capital allocation based on market supply and demand - As of **June 30, 2025**, the total amount of bills payable and accounts payable was **RMB 1,073.98 million**, a decrease of **11.56%** compared to December 31, 2024[90](index=90&type=chunk) - This was mainly due to the Group's procurement arrangements based on market supply and demand and effective allocation of capital utilization[90](index=90&type=chunk) [Treasury Policy](index=26&type=section&id=Treasury%20Policy) The Group adopts a prudent financial management strategy, closely monitoring liquidity, assessing customer credit to mitigate risk, and ensuring the liquid structure of assets, liabilities, and other commitments aligns with funding requirements - The Group adopts a prudent financial management strategy, maintaining a sound liquidity position during the reporting period[91](index=91&type=chunk) - It closely monitors the Group's liquidity position to ensure that the liquid structure of assets, liabilities, and other commitments meets funding needs[91](index=91&type=chunk) [Foreign Exchange Risk](index=26&type=section&id=Foreign%20Exchange%20Risk) The Group's transactions, most assets, and all liabilities are denominated in RMB, resulting in extremely low foreign exchange risk, with no financial instruments used to hedge foreign currency risk during the reporting period - The Group's transactions are denominated in RMB, and most of its assets and all its liabilities are denominated in RMB, resulting in extremely low foreign exchange risk[92](index=92&type=chunk) - For the six months ended **June 30, 2025**, the Group did not use any financial instruments to hedge foreign currency risk[92](index=92&type=chunk) [Interest Rate Risk](index=26&type=section&id=Interest%20Rate%20Risk) As of June 30, 2025, the Group had no bank borrowings bearing floating interest rates, indicating a low interest rate risk - As of **June 30, 2025**, the Group had no bank borrowings bearing floating interest rates[93](index=93&type=chunk) [Capital Gearing Ratio](index=26&type=section&id=Capital%20Gearing%20Ratio) As of June 30, 2025, the Group's capital gearing ratio was 57.44%, an increase from 51.37% at year-end 2024 Capital Gearing Ratio | Date | Capital Gearing Ratio | | :--- | :--- | | June 30, 2025 | 57.44% | | December 31, 2024 | 51.37% | - The capital gearing ratio is calculated as net debt at period-end divided by total capital[95](index=95&type=chunk) [Other Information](index=27&type=section&id=Other%20Information) This section provides other important information for the six months ended June 30, 2025, including capital commitments, employee details, significant investments, asset pledges, contingent liabilities, and corporate governance, offering a comprehensive overview of the company's operations and governance [Capital Commitments](index=27&type=section&id=Capital%20Commitments) As of June 30, 2025, the Group had no capital commitments, consistent with the situation at year-end 2024 - As of **June 30, 2025**, the Group had no capital commitments (December 31, 2024: nil)[96](index=96&type=chunk) [Employee Information](index=27&type=section&id=Employee%20Information) As of June 30, 2025, the Group had 849 employees, an increase of 15 from the previous year, with total staff costs of RMB 47.57 million, and the Group focuses on employee development, offering competitive remuneration and training - As of **June 30, 2025**, the Group had **849 employees**, an increase of **15 employees** compared to June 30, 2024[97](index=97&type=chunk) - For the six months ended **June 30, 2025**, total staff costs were **RMB 47.57 million**, compared to **RMB 45.83 million** for the same period in 2024[97](index=97&type=chunk) - The Group provides competitive salaries and benefits and focuses on employee career development, regularly conducting internal and external training[97](index=97&type=chunk) [Significant Investments Held](index=27&type=section&id=Significant%20Investments%20Held) For the six months ended June 30, 2025, the Group held no significant investments - For the six months ended **June 30, 2025**, the Group had no significant investments[98](index=98&type=chunk) [Future Plans for Material Investments and Capital Assets](index=27&type=section&id=Future%20Plans%20for%20Material%20Investments%20and%20Capital%20Assets) During the reporting period and up to the date of this announcement, the Group had no future plans regarding material investments and capital assets - During the reporting period and up to the date of this announcement, the Group had no future plans regarding material investments and capital assets[99](index=99&type=chunk) [Material Acquisitions and Disposals of Subsidiaries, Associates, and Joint Ventures](index=27&type=section&id=Material%20Acquisitions%20and%20Disposals%20of%20Subsidiaries%2C%20Associates%2C%20and%20Joint%20Ventures) For the six months ended June 30, 2025, the Group had no material acquisitions or disposals of subsidiaries, associates, or joint ventures - For the six months ended **June 30, 2025**, the Group had no material acquisitions or disposals of subsidiaries, associates, or joint ventures[100](index=100&type=chunk) [Pledges of Assets](index=27&type=section&id=Pledges%20of%20Assets) As of June 30, 2025, the Group had utilized total bank credit of RMB 1,455.82 million, secured by properties and plant with a carrying value of RMB 207.11 million and land use rights of RMB 65.82 million - As of **June 30, 2025**, the Group had utilized total bank credit of **RMB 1,455.82 million**[101](index=101&type=chunk) - Pledged assets include properties and plant with a carrying value of **RMB 207.11 million** and land use rights of **RMB 65.82 million**[101](index=101&type=chunk) [Assets with Restricted Ownership or Use Rights](index=27&type=section&id=Assets%20with%20Restricted%20Ownership%20or%20Use%20Rights) As of June 30, 2025, the Group's assets with restricted ownership or use rights totaled RMB 574.26 million, primarily including monetary funds pledged as guarantees for bank acceptance bills and borrowings, and bills receivable pledged to banks, along with other pledged assets - As of **June 30, 2025**, the Group's restricted monetary funds amounted to **RMB 297.73 million**, serving as guarantees for bank acceptance bills and borrowings[102](index=102&type=chunk) - Restricted bills receivable amounted to **RMB 3.60 million**, pledged to banks[102](index=102&type=chunk) - Other pledged assets totaled **RMB 272.93 million**, with total assets with restricted ownership or use rights amounting to **RMB 574.26 million**[102](index=102&type=chunk) [Contingent Liabilities](index=28&type=section&id=Contingent%20Liabilities) As of June 30, 2025, the Group had no material contingent liabilities, consistent with the situation at year-end 2024 - As of **June 30, 2025**, the Group had no material contingent liabilities (December 31, 2024: nil)[104](index=104&type=chunk) [Significant Events After Reporting Period](index=28&type=section&id=Significant%20Events%20After%20Reporting%20Period) As of the date of this announcement, there were no significant events after the reporting period requiring disclosure by the Group - As of the date of this announcement, there were no significant events after the reporting period requiring disclosure by the Group[105](index=105&type=chunk) [Interim Dividends](index=28&type=section&id=Interim%20Dividends) The Board does not recommend an interim dividend for the six months ended June 30, 2025, consistent with the same period in 2024 - The Board does not recommend the payment of an interim dividend for the six months ended **June 30, 2025** (2024 interim dividend: nil)[106](index=106&type=chunk) [Corporate Governance Practices](index=28&type=section&id=Corporate%20Governance%20Practices) For the six months ended June 30, 2025, the Company consistently complied with the code provisions of the Corporate Governance Code set out in Appendix C1 of the Listing Rules and will continue to review its practices to enhance corporate governance standards - For the six months ended **June 30, 2025**, the Company has consistently complied with the code provisions of the Corporate Governance Code set out in Appendix C1 of the Listing Rules[107](index=107&type=chunk) - The Company will continue to review its corporate governance practices to enhance its corporate governance standards[107](index=107&type=chunk) [Standard Code for Securities Transactions by Directors and Supervisors](index=28&type=section&id=Standard%20Code%20for%20Securities%20Transactions%20by%20Directors%20and%20Supervisors) The Company has adopted the Standard Code for Securities Transactions by Directors and Supervisors as set out in Appendix C3 of the Listing Rules and confirms that all directors and supervisors complied with it during the reporting period - The Company has adopted the Standard Code for Securities Transactions by Directors and Supervisors as set out in Appendix C3 of the Listing Rules as a code of conduct for directors and supervisors to deal in the Company's securities[108](index=108&type=chunk) - The Company confirms that all directors and supervisors complied with the required standards set out in the Standard Code for the six months ended **June 30, 2025**[108](index=108&type=chunk) [Purchase, Sale or Redemption of the Company's Listed Securities](index=28&type=section&id=Purchase%2C%20Sale%20or%20Redemption%20of%20the%20Company%27s%20Listed%20Securities) For the six months ended June 30, 2025, neither the Company nor its subsidiaries purchased, sold, or redeemed any of the Company's listed securities, and no treasury shares were held at period-end - For the six months ended **June 30, 2025**, neither the Company nor its subsidiaries purchased, sold, or redeemed any of the Company's listed securities[109](index=109&type=chunk) - As of **June 30, 2025**, the Company did not hold any treasury shares[109](index=109&type=chunk) [Audit Committee and Review of Interim Results](index=28&type=section&id=Audit%20Committee%20and%20Review%20of%20Interim%20Results) The Audit Committee, comprising three members, has reviewed the unaudited condensed consolidated interim financial statements for the six months ended June 30, 2025, and found them prepared in compliance with applicable accounting standards, rules, and regulations, with appropriate disclosures - The Audit Committee comprises **three members**, including two independent non-executive directors and one non-executive director[110](index=110&type=chunk) - The Audit Committee has reviewed the unaudited condensed consolidated interim financial statements for the six months ended **June 30, 2025**, and is of the opinion that they were prepared in compliance with applicable accounting standards, rules, and regulations, and that appropriate disclosures have been made[110](index=110&type=chunk) [Publication of Information on HKEX and Company Website](index=29&type=section&id=Publication%20of%20Information%20on%20HKEX%20and%20Company%20Website) This announcement has been published on the Company's and HKEX websites, and the interim report will be dispatched to shareholders and posted on these websites in due course - This announcement has been published on the Company's website (www.chmyy.com) and the HKEX website (www.hkexnews.hk)[111](index=111&type=chunk) - The Company's interim report for the six months ended **June 30, 2025**, will be dispatched to the Company's shareholders and posted on the aforementioned websites in due course[111](index=111&type=chunk)

格隆汇8月15日丨创美药业(02289.HK)公布，公司将于2025年8月28日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及审议派发中期股息的建议（如 有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致的 任何損失承擔任何責任。 嚴京斌 主席 Charmacy Pharmaceutical Co., Ltd. 創美藥業股份有限公司 中國汕頭，二零二五年八月十五日 （在中華人民共和國註冊成立之股份有限公司） （股份代號：2289） 董事會會議通告 創美藥業股份有限公司（｢本公司｣）董事會（｢董事會｣）謹此宣佈，董事會會議將於二 零二五年八月二十八日（星期四）舉行，藉以（其中包括）審議及批准本公司及其附屬 公司截至二零二五年六月三十日止六個月的中期業績及其發佈，並考慮宣派中期股息 （如有）。 承董事會命 創美藥業股份有限公司 於本公告日期，本公司執行董事為姚創龍先生、鄭玉燕女士與張寒孜女士；本公司非執 行董事為嚴京斌先生、付征女士與徐飛先生；及本公司獨立非執行董事為李漢國先生、 尹智偉先生與關鍵先生（又名關蘇哲）。 ...

Summary of Key Points Core Viewpoint - A total of 142 stocks reached their 52-week highs as of August 12, with notable performers including Yingmei Holdings (02028), Elite Group (01775), and Fuying Global Group (01620) achieving high rates of 164.89%, 84.78%, and 40.63% respectively [1]. Stock Performance - **Top Performers**: - Yingmei Holdings (02028) closed at 0.223 with a peak of 0.249, marking a 164.89% increase [1]. - Elite Group (01775) closed at 0.350 with a peak of 0.425, reflecting an 84.78% increase [1]. - Fuying Global Group (01620) closed at 0.180, reaching its peak at 0.180, showing a 40.63% increase [1]. - **Other Notable Stocks**: - Aoya Group (02425) increased by 34.36% [1]. - Fuyiy International Holdings (01470) saw a rise of 28.30% [1]. - Huajian Medical (01931) experienced a 27.58% increase [1]. 52-Week High Rankings - The ranking of stocks that reached their 52-week highs includes: - Yingmei Holdings (02028) at 164.89% [1]. - Elite Group (01775) at 84.78% [1]. - Fuying Global Group (01620) at 40.63% [1]. 52-Week Low Rankings - The report also highlights stocks that reached their 52-week lows, with notable declines including: - Jiadeng International Group (08153) at -15.25% [4]. - Kun Group (00924) at -12.86% [4]. - Zhongjia Guoxin (00899) at -10.00% [4].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 創美藥業股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02289 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 108,000,000 | RMB | | 1 RMB | | 108,000,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 108,000,000 | RMB | | 1 RMB | | 108,000,000 | 本月底法定/註冊股本總額： RMB 108,000,000 備註： 因本 ...

Company Performance - The company ranked 35th among the top 100 wholesale enterprises in China based on revenue from its principal business in 2023[3]. - The company ranked 6th among pharmaceutical distribution businesses in Guangdong Province[3]. - For the year ended December 31, 2024, the Group's operating revenue increased by 0.72% to RMB 4,435.46 million from RMB 4,403.63 million in 2023[22]. - Gross profit rose by 10.94% to RMB 324.76 million, with a gross profit margin increase from 6.65% in 2023 to 7.32% in 2024[22]. - Net profit attributable to shareholders of the parent company increased by 3.78% to RMB 53.28 million from RMB 51.34 million in 2023[22]. - The total operating revenue for the year ended December 31, 2024, was RMB 4,435.5 million, representing a slight increase from RMB 4,403.6 million in 2023[38]. - The net profit attributable to shareholders of the parent company for 2024 was RMB 53.3 million, up from RMB 51.3 million in 2023, indicating a growth of approximately 3.8%[38]. - The total assets as of December 31, 2024, reached RMB 3,456.6 million, an increase from RMB 3,247.7 million in 2023, reflecting a growth of about 6.4%[38]. Market Position and Strategy - The company has been recognized as an Excellent Pharmaceutical Logistics and Distribution Enterprise for four consecutive years and has received multiple awards for its logistics capabilities[5]. - The company has been consistently ranked among the "Guangdong Top-500 Enterprises" and the "Top-100 Wholesalers in the Pharmaceutical Distribution Industry" for over a decade[24]. - The Group aims to strengthen its competitive edge through the establishment of Guangdong Charmacy Pharmaceutical Logistics Co., Ltd. in June 2024, focusing on domestic freight forwarding services[20]. - The Group plans to focus on the non-bidding market and build a high-quality development path in 2025, enhancing its logistics distribution system and third-party logistics service competitiveness[27]. - The Group's strategy includes leveraging artificial intelligence and big data to enhance operational efficiency and meet evolving pharmaceutical distribution needs[28]. - The company aims to enhance competitiveness in third-party logistics services by leveraging artificial intelligence for operational decision-making[32]. - The company is committed to exploring high-quality development pathways and unlocking new profit engines for sustainable growth[32]. Digital Transformation and Innovation - The pharmaceutical distribution industry in China is experiencing profound changes, shifting towards supply chain management, digital operations, and professional services[20]. - The pharmaceutical distribution industry is transitioning towards a model focused on supply chain management, digital operations, and professional services[41]. - The digital transformation of pharmaceutical distributors is being driven by regulatory constraints and medical insurance policies, further deepening their operational capabilities[59]. - The company aims to achieve intelligent management of the entire process and improve efficiency through the integration of digitalization and AI technology[96]. - The Group is leveraging digital technologies to improve service capabilities in the pharmaceutical supply chain, enhancing the "last mile" service through advanced technologies like big data and AI[87]. - The company is exploring AI applications to enhance operational efficiency, with successful automation upgrades in financial management and logistics[72]. - The company aims to establish an end-to-end intelligent business ecosystem through full-process digital integration and continuous iteration of AI models[73]. Logistics and Distribution Network - The company operates a modern information system covering the entire pharmaceutical distribution supply chain, including procurement, sales, warehousing, transportation, and delivery[3]. - The company has established a highly efficient delivery mechanism, providing three deliveries per day within a 10-kilometer radius[3]. - The company has four modern pharmaceutical logistics centers and a professional marketing service team[3]. - The Group established a large pharmaceutical sorting and distribution centre in Shenzhen, enhancing its influence in the Greater Bay Area's pharmaceutical terminal market and promoting the coordinated upgrading of the regional pharmaceutical industry chain[76]. - The Group's logistics network adheres to unified Good Supply Practice (GSP) management standards, ensuring standardized storage conditions and enhancing service quality[77]. - The Group's third-party pharmaceutical logistics business saw a year-on-year increase of 30% in the number of clients and over 55% growth in corresponding revenue as of December 31, 2024[81]. Customer and Supplier Relationships - As of December 31, 2024, the Group's distribution network covered 14,429 customers, including 13,744 pharmaceutical retail customers, and collaborated with 1,206 suppliers[19]. - The company has strengthened cooperation with 1,206 suppliers, including 623 pharmaceutical manufacturers and 583 distributor suppliers, representing an increase of 60 suppliers compared to last year[65]. - The company distributed 12,810 product specifications as of December 31, 2024, an increase from 12,212 in 2023, with 4,759 being Chinese patent medicines and 4,664 Western medicines[66][65]. Financial Management and Costs - Operating costs remained stable at RMB 4,110.70 million for 2024, slightly down from RMB 4,110.89 million in 2023[114]. - Selling expenses decreased by 1.65% to RMB 120.44 million in 2024, compared to RMB 122.47 million in 2023[122]. - Management expenses increased by 15.33% to RMB 54.82 million in 2024, primarily due to increased employee compensation expenses[123]. - Finance costs surged by 47.09% to RMB 62.29 million in 2024, driven by increased bank loans and corresponding interest expenses[124]. - Income tax expenses rose by 11.40% to RMB 17.91 million in 2024, up from RMB 16.07 million in 2023[125]. Leadership and Governance - The company has a diverse leadership team with extensive experience in finance, management, and the pharmaceutical industry, enhancing its strategic decision-making capabilities[182]. - The Group is focused on expanding its market presence and enhancing product management through experienced leadership[176]. - The leadership team is well-equipped to navigate the complexities of the pharmaceutical market, leveraging their combined expertise for strategic initiatives[190].